Clinical Trial Update: Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates the combination of Rituximab with autologous effector lymphocytes in follicular lymphoma patients responding to first-line ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Autologous effector lymphocytes
• Rituximab (rituximab)

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Follicular Lymphoma, Follicular Non-Hodgkin´s Lymphoma | Phase 2 | Status: UNKNOWN